PALO ALTO, CA – May 15, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 – 20, 2023.

Additionally, members of BridgeBio leadership, including Neil Kumar, CEO and founder, will be presenting on multiple panels discussing drug development and accelerated approval for gene therapy.

Oral presentation details: 

Initial biomarker and clinical findings from the CANaspire Canavan disease gene therapy trial: Exploration of connections between NAA and disease severity

Presenter: Florian Eichler, M.D., director of the leukodystrophy service at Massachusetts General Hospital, Center for Rare Neurological Disease and lead CANaspire investigator

Session date/ time: Saturday, May 20 at 10:15 am – 12:00 pm PT 

Presentation time: 11:15 am – 11:30 am PT
Location: Concourse Hall 150 & 151, Los Angeles Convention Center 

Session title: Gene and cell therapy trials in progress 

Abstract number: 358 


Additional panel details:  

Accelerated approval for cell and gene therapies 

Date & time: Wednesday, May 17 at 9:00 am – 9:45 am PT 

Panelist: Adora Ndu, Pharm.D., J.D., chief regulatory and interim legal officer of BridgeBio 

Location: Room 515 AB, Los Angeles Convention Center

Venture capital in the gene and cell therapy space 

Date & time: Friday, May 19 at 8:00 am – 9:45 am PT 

Co-chair: Eric David, M.D., J.D., CEO of BridgeBio Gene Therapy 

Panelist: Neil Kumar, Ph.D., founder and CEO of BridgeBio 

Location: Concourse Hall 152 & 153, Los Angeles Convention Center 


Evolution of genetic medicines: Navigating the challenges and synergies among therapeutic modalities 

Date & time: Friday, May 19 at 10:15 am – 12:30 pm PT  

Panelist: Eric David, M.D., J.D., CEO of BridgeBio Gene Therapy 

Location: Room 411, Los Angeles Convention Center 


Accelerate your drug development program in rare disease with robust natural history data: An evolving space 

Session title: How to design a natural history study that regulators and clinicians support 

Date & time: Friday, May 19 at 10:15 am – 12:00 pm PT 

Panelist: Adam Shaywitz, M.D., Ph.D., chief medical officer at BridgeBio Gene Therapy 

Location: Room 408 AB, Los Angeles Convention Center 


About BridgeBio Pharma, Inc. 

BridgeBio Pharma Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on LinkedIn and Twitter. 


BridgeBio Media Contact: 

Vikram Bali 

[email protected]